Juno Therapeutics January 2017 Corporate Presentation

Juno Therapeutics presents its progress as a leading T-cell engineering company, highlighting advancement of JCAR017, its potential best-in-class CD19 product candidate expected on market as early as 2018. The presentation covers pipeline expansion beyond CD19 including CD22 and myeloma programs, plus strategic partnership with Celgene for global manufacturing and commercialization.